Alexey Pavlov, Director of the Nanolek Biomedical Complex, shared insights with Sber Pro on the biotechnology development and the company’s strategic direction:

"Nanolek is focused both on creating new vaccines and significantly expanding its production capabilities. Last year, our quadrivalent recombinant human papillomavirus (HPV) vaccine, Tsegardex, successfully completed its preclinical studies and Phase III clinical trials in adults. In 2024, Nanolek obtained approval from the Ministry of Health to begin Phase III trials of the HPV vaccine in children and adolescents aged 9 to 17."

Nanolek specializes in the development of innovative biotechnological products. By 2032, the company plans to invest an additional 5 billion rubles in production expansion. These funds will support the development and manufacturing of biotechnological substances, which are raw materials for drug production, and a vaccine against human papillomavirus, including formulations for children.